摘要
目的:探讨佤族和汉族癌痛患者阿片类药物需求量是否存在差异。方法:回顾性收集2020年1月~2022年12月在某院就诊的佤族和汉族癌痛患者病例,将汉族癌痛患者纳入对照组(n=232),佤族癌痛患者纳入观察组(n=30),统计并分析两组患者一般资料及阿片类药物需求量。结果:两组患者癌痛程度均为中重度,年龄、性别、体重指数、TNM分期、初始数字疼痛分级法(NRS)评分、肿瘤类型、辅助用药和阿片类药物治疗史等一般资料比较均无统计学差异(P>0.05)。观察组24h-阿片类药物需求量、体重-24h-阿片类药物需求量均少于对照组(P<0.05),两组体重-体表面积-24h-阿片类药物需求量比较无统计学差异(P>0.05),但观察组少于对照组。结论:佤族与汉族癌痛患者阿片类药物需求量存在差异,表现为佤族患者阿片类药物需求量少于汉族患者。
Objective:To determine whether there is difference in the prescribed amount of opioids between Wa and Han Chinese patients with cancer pain.Methods:The data of Wa and Han Chinese patients with cancer pain who visited a hospital from January 2020 to December 2022 were retrospectively collected.The Han Chinese patients with cancer pain were included in the control group(n=232)and the Wa Chinese patients with cancer pain were included in the observation group(n=30).The general data and prescribed amount of opioids were statistically analyzed for the two groups.Results:It was noted that all patients in the two groups had moderate to severe cancer pain,and there was no statistically significant difference in age,sex,body mass index,TNM stage,initial NRS score,tumor type,adjuvant medication or previous opioid treatment between the two groups(P>0.05).The 24h-prescribed amount of opioids and body weight-24h-prescribed amount of opioids in the observation group were both less than those in the control group(P<0.05).The body weight-body surface area-24h-prescribed amount of opioids showed no statistically significant difference between the two groups(P>0.05),but was lower in the observation group as compared with the control group.Conclusion:There are differences in the prescribed amount of opioids between Wa and Han Chinese patients with cancer pain,as demonstrated by less amount prescribed for Wa Chinese patients as compared with the Han Chinese patients.
作者
李新蕊
潘兴
赵永艳
张光云
段宏民
冯金象
LI Xin-rui;PAN Xing;ZHAO Yong-yan;ZHANG Guang-yun;DUAN Hong-min;FENG Jin-xiang(College of Pharmacy,Dali University,Dali 671003,China;Department of Science and Education,the People's Hospital of Lincang,Lincang 677000,China;Department of Clinical Pharmacy,the People's Hospital of Lincang,Lincang 677000,China;Department of Oncology,the People's Hospital of Lincang,Lincang 677000,China)
出处
《中国合理用药探索》
CAS
2024年第1期87-91,共5页
Chinese Journal of Rational Drug Use
基金
云南省教育厅科学研究基金项目(2023Y1005)
临沧市科技创新团队(202204AC100002-TD04)。
